HOME >> MEDICINE >> NEWS
Neural transplants provide persistent benefit in patients with Huntington's disease

Neuronal transplantation in Huntington's disease provides a period of improvement and stability of several years, according to an Article published online today (Monday February 27, 2006) by The Lancet Neurology.

Intracerebral cell therapy, which aims to substitute striatal neurons lost to Huntington's disease by striatal neuroblasts and neural precursors obtained from embryos after elective abortion, has proven beneficial in patients with the disease. Theoretical projection models suggest that the clinical effects of grafting will lead to an initial improvement followed by a period of secondary decline due to the ongoing disease process. However, follow-up has not been long enough to assess the duration of clinical benefit of the treatment up to now.

Anne-Catherine Bachoud-Lvi (Henri Mondor Hospital, France) and colleagues have previously shown, in a pilot study, that intracerebral neural grafts lead to motor and cognitive improvement in patients with Huntington's disease 2 years after the procedure. In their current article, they present data for five patients from their pilot study, assessed annually for up to 6 years after neural grafting.

The procedure provided long-term clinical benefits to three patients in parallel with long-lasting focal improvement in brain metabolic activity. Progression of the disease led to heterogeneous secondary clinical alterations and changes of cerebral metabolism.

Whereas neuronal transplantation is not a permanent cure for Huntington's disease, it does provide a period of improvement and stability. Although neuroprotective treatment seems to be unavoidable in the disease, improvement of the surgical procedure and in patient selection could improve the therapeutic value of neuronal transplantation. Bachoud-Lvi concludes: "Neuroprotection could stop the disease, but only a graft can restore lost function."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
26-Feb-2006


Page: 1

Related medicine news :

1. Neural networking nanotubes
2. Neural development protein disproved as marker for schizophrenia
3. Neural cell transplants fight immune attack in mice with multiple sclerosis
4. Thymus transplants gives hope to babies with fatal immune disease
5. Outcomes for patients with hepatitis B who need liver transplants
6. Women given liver transplants outlive male recipients by around 4 years
7. How tumors respond to treatment prior to liver transplants may be useful in selecting recipients
8. National trial gives unprecedented support for steroid withdrawal in kidney transplants
9. Organ transplants just as successful in those with mental retardation
10. Liver transplants can be successful in HIV patients with Hepatitis B
11. Stem cell transplants improve recovery in animal models for stroke, cerebral palsy

Post Your Comments:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... A drug delivery system is ...
(Date:1/15/2014)... -- A novel wearable injector slightly larger than an Oreo ... patients to self-inject prescription drugs in the large doses ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   ... of injector that does not exist today for self-administration ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
Cached News: